Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.

Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH.

Gut Liver. 2013 Nov;7(6):696-703. doi: 10.5009/gnl.2013.7.6.696.

2.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168.

PMID:
23601249
3.

Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.

Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, Park SY, Tak WY, Kweon YO, Kim BS, Lee CH.

Clin Mol Hepatol. 2016 Mar;22(1):160-7. doi: 10.3350/cmh.2016.22.1.160.

4.

Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.

Pan T, Li XS, Xie QK, Wang JP, Li W, Wu PH, Zhao M.

Clin Radiol. 2014 Dec;69(12):e553-61. doi: 10.1016/j.crad.2014.09.007.

PMID:
25304928
5.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM.

J Hepatol. 2012 Oct;57(4):821-9. doi: 10.1016/j.jhep.2012.06.014.

6.

Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.

Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, Minamino T, Watanabe M, Kokubu S, Koizumi W.

BMC Gastroenterol. 2014 May 3;14:84. doi: 10.1186/1471-230X-14-84.

7.

Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T.

World J Gastroenterol. 2014 Sep 21;20(35):12581-7. doi: 10.3748/wjg.v20.i35.12581.

8.

A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.

Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM.

J Gastroenterol. 2015 Apr;50(4):445-54. doi: 10.1007/s00535-014-0978-3.

PMID:
25027973
9.

[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].

Turnes J, Díaz R, Hernandez-Guerra M, Gómez M, Castells L, Bustamante J, Espinosa MD, Fernández-Castroagudín J, Serrano T, Rendón P, Andrade R, Salgado M, Arenas J, Vergara M, Sala M, Polo BA, Granizo IM, Gonzálvez ML, Viudez A.

Gastroenterol Hepatol. 2015 Apr;38(4):263-73. doi: 10.1016/j.gastrohep.2014.11.001. Spanish.

PMID:
25583146
10.

Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.

Ye HH, Ye JZ, Xie ZB, Peng YC, Chen J, Ma L, Bai T, Chen JZ, Lu Z, Qin HG, Xiang BD, Li LQ.

World J Gastroenterol. 2016 Apr 7;22(13):3632-43. doi: 10.3748/wjg.v22.i13.3632.

11.

Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.

Kermiche-Rahali S, Di Fiore A, Drieux F, Di Fiore F, François A, Scotté M.

World J Surg Oncol. 2013 Aug 2;11(1):171. doi: 10.1186/1477-7819-11-171.

12.

Sorafenib in liver function impaired advanced hepatocellular carcinoma.

Ji YX, Zhang ZF, Lan KT, Nie KK, Geng CX, Liu SC, Zhang L, Zhuang XJ, Zou X, Sun L, Zhang ZC.

Chin Med Sci J. 2014 Mar;29(1):7-14.

PMID:
24698672
13.

Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.

Edeline J, Crouzet L, Campillo-Gimenez B, Rolland Y, Pracht M, Guillygomarc'h A, Boudjema K, Lenoir L, Adhoute X, Rohou T, Boucher E, Clément B, Blanc JF, Garin E.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):635-43. doi: 10.1007/s00259-015-3210-7.

PMID:
26455499
14.

Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F.

World J Gastroenterol. 2014 Jan 21;20(3):786-94. doi: 10.3748/wjg.v20.i3.786.

15.

Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.

Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, Cai M, Shan H.

Radiology. 2014 Jul;272(1):284-93. doi: 10.1148/radiol.14131946.

PMID:
24708192
16.

Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.

Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1041-7. doi: 10.1016/j.ijrobp.2014.01.017.

PMID:
24661657
17.

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.

Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono T, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan..

Cancer Med. 2015 Dec;4(12):1836-43. doi: 10.1002/cam4.548.

18.

Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.

Li J, Wang L, Cong N, Shi C, Bu W, Song J, Chen H.

Hepatogastroenterology. 2014 Jun;61(132):954-7.

PMID:
26158148
19.

Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.

Zhou L, Li J, Ai DL, Fu JL, Peng XM, Zhang LZ, Wang JY, Zhao Y, Yang B, Yu Q, Liu CZ, Wang HM.

Jpn J Clin Oncol. 2014 Aug;44(8):711-7. doi: 10.1093/jjco/hyu068.

PMID:
24855686
20.

A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.

Shen A, Tang C, Wang Y, Chen Y, Yan X, Zhang C, Liu R, Wei X, Zhu Y, Zhang H, Wu Z.

J Clin Gastroenterol. 2013 Nov-Dec;47(10):871-80. doi: 10.1097/MCG.0b013e3182a87cfd. Review.

PMID:
24100749

Supplemental Content

Support Center